Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma

NCT02610556 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

130

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Cisplatin 2
DRUG: Docetaxel
DRUG: Cisplatin 1
RADIATION: Intensity-modulated radiotherapy

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]
[object Object]